Pharmaceutical Technology E-Alert:
Having trouble viewing this e-mail? Click here. 		You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile.
BLOG
EVENT CALENDAR
COLUMNS
WHITE PAPERS
THE MAGAZINE
  Pharmaceutical Technology Europe E-Alert
 
5 April 2012

IN THIS ISSUE
• Conflicts of interest
• Regenerative medicine
• Generic Lipitor
• User fees
• Swine flu vaccine

EMA gets tough on conflicts of interest
The EMA’s Management Board has introduced a range of new measures to strengthen and extend its conflicts of interest policy for scientific-committee members and experts, as well as for members of the management board. More...
 
UK invests in regenerative medicine
An initiative in the UK will pump £75 million ($120.2 million) into translational science, with the aim of transforming biological understanding into clinical impacts that will benefit patients and the UK economy. More...
 
Ranbaxy begins shipping generic Lipitor from Indian facility
Ranbaxy Laboratories has sent the first shipments of atorvastatin, the generic version of Pfizer’s Lipitor, to US markets from its new Mohali manufacturing facility located in Punjab, India. More...
 
Congress urged to move ahead on generic and biosimilar user fees
The Generic Pharmaceutical Association (GPhA) has reiterated its call in the US for Congress to move forward with user-fee proposals for generic drugs and biosimilar products. More...
 
Studies tie GSK vaccine to narcolepsy
Two studies published in the Public Library of Science appear to confirm a link between GlaxoSmithKline’s Pandemrix vaccine and cases of narcolepsy in children in Finland. More...
 
Join our community on LinkedIn
Want to discuss any of this week's news stories or any other hot topics in the industry? Then why not join our group on LinkedIn? More...
Key Topics:

Latest blog posts
Vaccine tied to narcolepsy
JOBS Act passage ? a boost for biopharma?
A cautionary note for developers of personalised medicine
More blog posts

Latest articles
Tackling solubility challenges
CMOs face a Kodak moment
Report from Brazil
More articles

Upcoming events
The Pharma Congress Production & Technology (24?25 April | Germany)
LogiPharma (24?26 April | Switzerland)
Mobile Pharma World Europe (24?27 April | The Netherlands)
More events

Products/Service Profiles
BASF Pharma Ingredients and Services

Kollicoat® Smartseal 30 D provides superior taste masking and moisture protection for bitter and moisture-sensitive APIs. The solvent-free aqueous dispersion is exceptionally easy to apply – for faster, more cost-effective processing.
Read more
 
Hospira One 2 One

Hospira One 2 One® contract development and fill-finish manufacturing of injectable products packaged in vials, PFS, cartridges, ampoules. Broad range of capabilities: Biologics; Potent drugs; Vaccines; Cytotoxics; Beta-lactams; Lyophilization.
Read more
 
New Mill

2-Day Webcast Auction Sale of Contract Pharmaceuticals Limited Niagara - April 18 & 19, Buffalo, NY, 500,000 Sq. Ft. Contract Processing & Packaging Facility.
Read more

 
Shimadzu

Supersonic flow
Shimadzu's LCMS-8030 features the most innovative technology found in a commercial tandem quadrupole mass analyzer. Combined with the class-leading Nexera UHPLC, both systems facilitate seamless LC/MS/MS analyses in a high-performance, high-speed flow, steadily and reliably.
Read more

 

Company Profile

TSI Incorporated
TSI Incorporated Introduces Innovative Solution for Real-time Viable Particle Detection.
TSI introduces the BioTrak™ Real-Time Viable Particle Counter for monitoring pharmaceutical cleanroom facilities. Read more

Event Profile

Biological Production Forum
24th-26th September 2012
Düsseldorf
Germany
The Biological Production Forum attracts senior level biopharmaceutical industry professionals working within manufacturing, process development and product operations. The global biological production industry is under pressure amidst challenging price restrictions, US health care reforms and reduced revenues. Read more



Survey
What has been the most significant development in biologic-based drug manufacturing over the past 10 years?
  Improvement in upstream yields 21%
 
  Advancement of single-use technologies or disposables 28%
     
  Application of quality-by-design principles 30%
     
  Improvements in downstream bioprocessing/purification 21%

This week we would like to know...

What is your opinion of FDA's new guidance on TV DTC advertising?

Click here to vote

Contact Us
Click here to contact editorial.

Click here to contact sales.

 
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact
information available to third parties for marketing purposes, please contact us by emailing [email protected] or by mail at Advanstar Communications Inc., Bridgegate Pavilion, 4A Chester Business Park, Wrexham Road, Chester, CH4 9QH, UK.